Vital Signs - Healthcare News - The Analysts Perspective - July Issue

Regular Price: USD 500.00

Special Price USD 450.00

10% OFF

* Required Fields

Regular Price: USD 500.00

Special Price USD 450.00


Be the first to review this product

This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biology's Series A funding round, Roche's investment in Stratos Genomics, and India's cap on drug prices.

Table of Contents

Vital Signs - Healthcare News - The Analyst's Perspective - July IssueVital Signs - July 2014This Week's Issue

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.